NCT02618356

Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer

A Phase II Clinical Study of Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer Failed of Standard Chemotherapy

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 82 (estimated)
• Sponsor: Fudan University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The primary endpoint is to evaluate the Median disease progression free survival (mPFS).

Detailed description

The primary endpoint is to evaluate the disease progression free survival (mPFS) of Raltitrexed combined with S-1 as treatment for patients with metastasizing colorectal cancer failed of standard chemotherapy

Conditions

• Metastatic Colon Cancer

Interventions

Type	Name	Description
DRUG	Raltitrexed and S-1	Raltitrexed 3mg/m2 intravenously guttae, d1 and S-1,bid,po,d1-d14,every three weeks for a cycle. BSA (body surface area) S-1 dosage \<1.25 m2 80 mg/d * 1.25m2 - \<1.5 m2 100 mg/d * 1.5 m2 120 mg/d

Timeline

• Start date: 2015-12-25
• Primary completion: 2017-11-01
• Completion: 2017-11-01
• First posted: 2015-12-01
• Last updated: 2017-10-02

Locations

1 site across 1 country: China